Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2025)
Legend Biotech (LEGN) posted Current Deferred Revenue of $11.3 million for Q4 2025, down 49.95% on a QoQ basis from $22.6 million in Q3 2025, and down 75.91% year-over-year from $46.9 million in Q4 2024.
Legend Biotech (LEGN) has 7 years of Current Deferred Revenue data on file, last reported at $11.3 million in Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 75.91% year-over-year to $11.3 million; the TTM figure through Dec 2025 stood at $11.3 million (down 75.91% YoY), while the FY2025 annual figure was $11.3 million, down 75.91% from the prior year.
- Current Deferred Revenue eased to $11.3 million in Q4 2025, from $22.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $237.2 million in Q3 2021 and bottomed at -$245.8 million in Q1 2022.
- A 5-year average of $24.2 million and a median of $36.4 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue surged 96471.42% — and 2022, when it plunged 95145.35%.
- Year by year, Current Deferred Revenue stood at -$60.6 million in 2021, then slumped by 305.4% to -$245.8 million in 2022, then soared by 121.56% to $53.0 million in 2023, then decreased by 11.53% to $46.9 million in 2024, then plunged by 75.91% to $11.3 million in 2025.
- The last three Current Deferred Revenue figures came in at $11.3 million (Q4 2025), $22.6 million (Q3 2025), and $33.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 22.58 Mn |
| Jun 30, 2025 | 33.18 Mn |
| Mar 31, 2025 | 39.54 Mn |
| Dec 31, 2024 | 46.90 Mn |
| Sep 30, 2024 | 63.16 Mn |
| Jun 30, 2024 | 74.85 Mn |
| Mar 31, 2024 | 63.25 Mn |
| Dec 31, 2023 | 53.01 Mn |
| Mar 31, 2022 | -245.85 Mn |
| Dec 31, 2021 | -60.64 Mn |
| Sep 30, 2021 | 237.22 Mn |
| Jun 30, 2021 | 252,628.00 |
| Mar 31, 2021 | 258,666.00 |
| Dec 31, 2020 | 55.01 Mn |
| Sep 30, 2020 | 245,641.00 |
| Jun 30, 2020 | 254,714.00 |
| Dec 31, 2019 | 46.29 Mn |